874279-26-2

Basic information

• Product Name: 4-(Dimethoxymethyl)-2-(methylsulfonyl)pyrimidine
• Synonyms: 4-(Dimethoxymethyl)-2-(methylsulfonyl)pyrimidine
• CAS NO: 874279-26-2
• Molecular Formula: C₈H₁₂N₂O₄S
• Molecular Weight: 232.25688
• Mol File: 874279-26-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-(Dimethoxymethyl)-2-(methylsulfonyl)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Dimethoxymethyl)-2-(methylsulfonyl)pyrimidine(874279-26-2)
• EPA Substance Registry System: 4-(Dimethoxymethyl)-2-(methylsulfonyl)pyrimidine(874279-26-2)

Safety Data

• Hazardous Substances Data: 874279-26-2(Hazardous Substances Data)

Usage

General Description

4-(Dimethoxymethyl)-2-(methylsulfonyl)pyrimidine is a chemical compound with the molecular formula C9H12N2O4S. It is a pyrimidine derivative with two methoxy groups and a methylsulfonyl group attached to the pyrimidine ring. 4-(Dimethoxymethyl)-2-(methylsulfonyl)pyrimidine is used in the synthesis of pharmaceuticals and agrochemicals, as well as in the preparation of various organic compounds. It has potential applications in the research and development of new drugs and in the production of crop protection chemicals. Its unique structure and properties make it a valuable building block for the creation of diverse chemical compounds for various industrial and scientific purposes.

Upstream product

• 67751-23-9 4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one 
• 67751-23-9 (E)-4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one 
• 6342-56-9 Pyruvic aldehyde dimethyl acetal 
• 180869-36-7 4-dimethoxymethyl-2-methylsulfanylpyrimidine 

Downstream Products

• 180869-38-9 4-(dimethoxymethyl)-N-methylpyrimidin-2-amine 
• 872707-78-3 2-(DIMETHYLAMINO)PYRIMIDINE-4-CARBOXALDEHYDE 
• 180869-39-0 2-(methylamino)pyrimidine-4-carbaldehyde 

Relevant articles and documents

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Myeloid cell leukemia 1 (Mcl-1) has emerged as an attractive target for cancer therapy. It is an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. Here we report the discovery of our clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. Starting from a fragment derived lead compound, we have conducted structure guided optimization that has led to a significant (3 log) improvement of target affinity as well as cellular potency. The presence of hindered rotation along a biaryl axis has conferred high selectivity to the compounds against other members of the Bcl-2 family. During optimization, we have also established predictive PD markers of Mcl-1 inhibition and achieved both efficient in vitro cell killing and tumor regression in Mcl-1 dependent cancer models. The preclinical candidate has drug-like properties that have enabled its development and entry into clinical trials.

Macrocyclic MCL-1 inhibitors and methods of use

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.